How to Live Longer and Feel Better - Even with Cancer

Journal of Orthomolecular Medicine

Volumn 11, Issue 3, 1996, Pages 147-167

  Hoffer, A ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000790561     PISSN: 03170209     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Pauling L: Orthomolecular Psychiatry, Science 1968;160:265-271.
2. Hoffer A, Osmond H, Callbeck MJ & Kahan I: Treatment of Schizophrenia with Nicotinic Acid and Nicotinamide. J Clin Exper Psychopathol, 1957; 18:131-158.
3. Hoffer A & Osmond H: How To Live With Schizophrenia. New York, University Books, 1966. New and Revised Ed. New York, Citadel Press, 1992.
4. Hoffer A: Treatment of schizophrenia with a therapeutic program based upon nicotinic acid as the main variable. In ed. O Walaas, Molecular Basis of Some Aspects of Mental Activity, Vol II, New York, Academic Press, 1967.
5. Hoffer A: Mechanism of action of nicotinic acid and nicotinamide in the treatment of schizophrenia. In eds. DR Hawkins and L Pauling: Orthomolecular Psychiatry, San Francisco, WH Freeman and Co, 1973.
6. Hoffer A: Some theoretical principles basic to orthomolecular psychiatric treatment. In ed. L Hippchen, Ecologic-Biochemical Approaches to Treatment of Delinquents and Criminals. New York. Van Nostrand-Reinhold Co, 1978; 31-55.
7. Hoffer A: Chronic schizophrenic patients treated ten years or more. J. Orthomolecular Medicine, 1994; 9: 7-37.
8. Altschul R, Hoffer A & Stephen JD: Influence of Nicotinic Acid on Serum Cholesterol in Man. Arch Biochem Biophys, 1955; 54: 558-559.
9. Parsons WB, Achor RWP, Berge KG et al: Changes in concentration of blood lipid levels following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations. Proc. Staff. Meet. Mayo Clin 1956; 31: 377-90
10. Parsons WB: Clinical alternatives. coronary heart disease. In ed. GV Mann: The Dietary Sense and Nonsense. An Evaluation by Scientists. Great Britain, Janus Publishing Co. 1993.
11. Pauling L: Vitamin C and The Common Cold San Francisco, WH Freeman, 1971.
12. Cameron E & Pauling L: Cancer and Vitamin C. Palo Alto, CA, Linus Pauling Institute of Science and Medicine, 1979.
13. Cameron E & Pauling L: Cancer and Vitamin C. Updated and Expanded. Philadelphia, Camino Books, 1993.
14. Hoffer J: Nutrients as biologic response modifiers. In ed. P Quillin & RM: Adjuvant Nutrition in Cancer Treatment. Williams. 1992 Symposium Proceedings, Cancer Treatment Research Foundation and American College of Nutrition, Cancer Treatment Research Foundation, 3455 Salt Creek Lane Suite 200, Arlington Heights, IL 60005-1090, 1993.
15. Hoffer A: Treatment of organic psychosis with nicotinic acid (A Single Case). Dis Nerv Syst, 1965; 26: 358-360.
16. Hoffer A, Osmond H, Callbeck MJ & Kahan I: Treatment of schizophrenia with nicotinic acid and nicotinamide. J Clin Experim Psychopathol, 1957; 18:131-158.
17. Jacobson EL: Niacin deficiency and cancer in women. J American College of Nutrition 1992; 11: 597-637.
18. Jacobson EL & Jacobson MK: A biomarker for the assessment of niacin nutriture as a potential preventative factor in carcinogenesis. J Intern Med , 1993; 233: 59-62.
19. Hoffer A: Orthomolecular Medicine for Physicians. New Canaan, CT, Keats Publ. 1989.
20. Pauling L: Biostatistical analysis of mortality data for cohorts of cancer patients. Proc Nat Acad Sci USA, 1989; 86:3466-3488.
21. Pauling L & Herman Z: Criteria for the validity of clinical trials of treatments of cohorts of cancer patients based on the Hardin Jones principle. Proc Nat Acad Sci USA, 1989; 86: 6835-6837.
22. Hoffer A & Pauling L: Hardin-jones bio-statistical analysis of mortality data for cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiving large regular oral doses of vitamin C and other nutrients with similar patients not receiving those doses. J Orthomolecular Medicine, 1990; 5:143-154.
23. Hoffer A & Pauling L: Hardin-jones biostatistical analysis of mortality data for a second set of cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiving large regular oral doses of vitamin C and other nutrients with similar patients not receiving these doses. J Orthomolecular Medicine, 1993; 8: 1547-1567.
24. Hoffer A: Orthomolecular Oncology. In ed. P Quillin & RMWilliams, Adjuvant Nutrition in Cancer Treatment. Cancer Treatment Research Foundation, 3455 Salt Creek Lane Suite 200, Arlington Heights, IL 60005-1090: 1994.
25. Hoffer A (With Major Contributions by Linus Pauling), Quarry Press, in press (due 1997).
26. Pauling L: Quoted in "The Nutrition Reporter" Challem J, 1992; 3: 8.
27. Hoffer A: Orthomolecular oncology and survival. Adjuvant Nutrition in Cancer Treatment Symposium. San Diego, CA, March 17-19, 1994.
28. Bliznakov EG & Hunt GL: The Miracle Nutrient Coenzyme Q10. Toronto. Bantam Books, 1987.
29. Folkers K, Brown R, Judy WV & Morita M: Survival of cancer patients on therapy with Coenzyme Q10. Biochem Biophys Res Comm, 1993; 192: 241-245.
30. Levine AM: The importance of hope. West J Med, 1989; 150: 609.
31. Sapolsky RM: On human nature. The Sciences 1994; 34:10-14.
32. Matthews SB, Henderson AH & Campbell AK: The adrenochrome pathway: The major route for adrenalin catabolism by polymorphonuclear leucocytes. J Mol Cell Cardiol 1985; 17: 339-348.
33. Bindoli A, Rigobello MP & Deeble DJ: Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radical Biology & Medicine 1992;13: 391-405.
34. Dhalla KS, Ganguly PK, Rupp H, Beamish RE & Dhalla NS: Measurement of adrenolutin as an oxidation product of catecholamines in plasma. Molecular and Cellular Biochemistry 1989; 87: 85-92.
35. Hoffer A & Osmond H: The Hallucinogens. New York, Academic Press, 1967.
36. Hoffer A, Osmond H & Smythies J: Schizophrenia: A New Approach. II. Results of a Years Research. J Ment Science 1954;100: 29-45.
37. Hoffer A: Adrenochrome and adrenolutin and their relationship to mental disease. In eds. Garattini S & Ghetti V: Psychotropic Drugs. London, Elsevier Press, 1957; 10-20.
38. Hoffer A: The effect of adrenochrome and adrenolutin on the behavior of animals and the psychology of man. Int Rev Neurobiology 1962; 4: 307-371.
39. Hoffer A: The adrenochrome hypothesis of schizophrenia revisited. J Orthomolecular Psychiatry 1981;10: 18-118.
40. Hoffer A: Oxidation-reduction in the brain. J Orthomolecular Psychiatry, 1983; 12: 292-301.
41. Hoffer A & Osmond H: The adrenochrome hypothesis and psychiatry. J Orthomolecular Medicine, 1990; 5: 32-45.
42. Smythies J: On the function of neuromelanin. Proc Roy Soc (London) B2, 1996; 63: 491-496.
43. Smythies J: Hallucinogenic drugs. Encyclopedia of Neuroscience. In press, 1996.
44. Smythies J: The role of ascorbate in brain: therapeutic implications. J Roy Soc of Med 1996; 89: 241.
45. Smythies J: Disturbances of one-carbon metabolism in neuropsychiatric disorders: a review. Submitted to Biological Psychiatry, 1996.
46. Hoffer A: Schizophrenia: An Evolutionary defence against severe stress. Townsend Letter for Doctors and Patients #151/152 Feb/Mar 1996.
47. Nauts HC: Bacterial products in the treatment of cancer: past, present and future. In eds. Jeljaszewics J, Pulverer G, Rostowski W: Bacteria and Cancer, New York. Academic Press 1982.
48. Kanofsky JD, Norkus EP, Geller B, Lowinger R, Kanofsky PB & Kennedy GK: Schizophrenia, lung cancer and vitamin C. American Psychiatric Association, Poster Session, Philadelphia, May 1994.
49. Falk R: Personal communication, 1995.
50. Holt JAG: Letter, September 21, 1993, Microwave Therapy Center, 311 Outram St., W. Perth, Australia, 6005.
51. Huxley J, Mayr E, Osmond H & Hoffer A: Schizophrenia as a genetic morphism. Nature, 1964; 204: 220-221.
52. Brown JS & Foster HD: Schizophrenia: an update of the selenium deficiency hypothesis. J Orthomolecular Medicine, In press, 1996.
53. Edelman E: Natural Healing for Schizophrenia. A Compendium of Nutritional Methods. Eugene, OR, Borage Books, 1996.
54. Hoffer A: The psychophysiology of cancer. J Asthma Res, 1970; 8: 61-76.
55. Nakatsugawa S & Sugahara T: Differential action on cancer and normal tissue by adrenochrome monaminoguanidine methane-sulfonate and cytochrome C combined with radiotherapy. Int J of Radiation Oncology, Biology, Physics 29:635-638, 1994.
56. Sugamoto K, Kimura H, Kawashima H, Itojima T, Aoyama T & Sugahara T: Radioprotective effects of adrenochrome monoamino-guanidine methanesulfonate (AMM) on irradiated C57B1 mice and the survival of GM-CFC, a hemotopoietic progenitor cell. J Radiat Res, 29:211-219, 1988.
57. Yamashita H, Okura J & Izumi K: Protective effect of adrenochrome monoguanylhydrazone methanesulfonate (S-Adchon) on the hematopoietic organ as revealed in irradiated cancer patients. J Radiat Res 12:41-50, 1971.
58. Kim JH, Kim SH, He S, Dragovic J, Brown S: Use of vitamins as adjunct to conventional cancer therapy. Second Denver Conference on Nutrition and Cancer, Denver, CO, Sept 7-11, 1994. In Nutrients in Cancer Prevention and Treatment. Eds. Prasad KN, Santamaria L & Williams RM, Humana Press, New Jersey, 363-372, 1995.
59. Agnew N & Hoffer A: Nicotinic acid modified lysergic acid diethylamide psychosis. J Ment Science, 101:12-27, 1955.
60. Stone I: The Healing Factor: Vitamin C against Disease. Grosset and Dunlap, New York, 1972.
61. Pauling L: How To Live Longer and Feel Better. WH Freeman and Company, New York, NY, 1986.
62. 3 (Niacin). Keats Pub, New Canaan, CT, 1984.
63. McCracken RD: Niacin and Human Health Disorders. Hygea Publishing Co., 635 Peterson St., Fort Collins, CO, 80524.
64. Hoffer A & Walker M: Smart Nutrients - A Guide to Nutrients That Can Prevent and Reverse Senility. Avery Publishing Group, Garden City Park, NY, 1994.
65. Hoffer A: Hoffer's Law of Natural Nutrition. Quarry Press, Kingston, ON, 1996.
66. Hoffer A & Walker M: Putting It All Together - The New Orthomolecular Nutrition. Keats Publishing Inc, 27 Pine Street, Box 876, New Canaan, CT 06840-0876, 1994.
67. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Amer Coll of Cardiology, 8:1245-1255, 1986.
68. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA & Willett WC: Vitamin E consumption and the risk of coronary heart disease in men. New England J Med 1993; 328: 1450-1456. In this paper there is no reference to the work done by the Shute Brothers in Ontario about 50 years ago. Their work had already established the enormous value of vitamin E in the treatment of coronary disease and other diseases.
69. Stampfer MJ, Hennekens CH, Manson J, Colditz GA, Rosner B & Willett WC: Vitamin E consumption and the risk of coronary disease in women. New England J Med 1993; 328: 1444-1449.
70. Prasad, KN Chairperson. Second Denver Conference on Nutrition and Cancer. Sept 7-11, 1994, Denver, Colorado. In eds. Prasad N, Santamaria L & Williams RM: Nutrients in Cancer Prevention and Treatment. New Jersey, Humana Press, 363-372, 1995.
71. Prasad KN: Cellular basis of using multiple antioxidant vitamins in cancer prevention and treatment. Nutrition in Cancer Treatment Symposium, Tampa, Florida, 1995.
72. Fornstedt B: Role of catechol autooxidation in the degeneration of dopamine neurons. Acta Neural Scand, Suppl. 1990; 129: 12-14.
73. Mann DMA & Yates PO: Possible role of neuromelanin in die padiogenesis of Parkinson's disease. Mech Age Dev, 1983; 21: 193-203.
74. Olanow CW: Oxidation reactions in Parkinson's disease. Neurology 40 (Suppl 3) 1990: 32-38.
75. Fahn S & Cohen G: The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Annals Neurology,1992; 32:804-812.
76. Jenner P: Oxidative damage in neuro-degenerative disease. The Lancet 1994; 344: 796-798.
77. Hoffer A: L-dopa: an hallucinogen. Schizophrenia 1970; 2:37, and 1970; 2:127.
78. Hoffer A: L-dopa: an hallucinogen. Schizophrenia 1970; 2:37, and 1970; 2:127.
79. Hoffer A: Dopamine, noradrenalin and adrenalin metabolism to methylated or chrome indole derivatives: two pathways or one? J Orthomolecular Psychiatry 1985; 14: 262-272.
80. Birkmayer W & Birkmayer GJD: Nicotinamide adenine dinucleotide (NADH): the new approach in the therapy of Parkinson's disease. Ann Clin Lab Sci 1989; 19: 38-43.
81. Birkmayer JGD, Vrecko C, Volc D & Birkmayer W: Nicotinamide adenine dinucleotide (NADH) - a new therapeutic approach to Parkinson's disease. Acta Neurol Scand, Suppl. vol. 8, 1993; 146P: 32-35.
82. Birkmayer JGD: Nicotinamide adenine dinucleotide (NADH) the new therapeutic approach for improving dementia of the Alzheimer's type. Forschungs- und Lehreinrichtung des Birkmayer Instituts fur Parkinsontherapie. Vienna, Austria. Menuco Corp., 350 Fifth Ave., Suite 7509, New York, NY 10118.
83. Birkmayer JGD & Birkmayer W: The coenzyme nicotinamide adenine dinucleotide (NADH) as biological antidepressive agent. Experience with 205 Patients. New Trends in Clinical Neuropharmacology 1991; 5: 19-25 .
84. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P & Marsden CD: Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem 1990; 54: 823-827.